In preparation for an IND submission for Inflammasome ASC Inhibitor IC 100 and a subsequent Phase 1 trial in healthy ... of ...

New insights and emerging scientific trends incorporated into our ACLF development plan, with data readout from 4 clinical trials anticipated by the end of 2025, including data from 3 new clinical ...

Fructose, the most common food sweetener, is widely used in processed sugary beverages, candies, and baked goods. Excessive ...

CVN293 was generally well-tolerated in healthy volunteers for up to 14-days of continuous dosingDose-dependent exposure was ...

MRT-6160, VAV1-directed MGD for immune-mediated conditions In September, Monte Rosa presented preclinical data at the Inflammasome Summit demonstrating that its development candidate MRT-8102, a first ...

A new therapy may delay Alzheimer's disease progression by years, according to a study by researchers at Texas A&M University ...

“With our potential best-in-class NLRP3 inhibitors, we believe we are well positioned to unlock the vast therapeutic potential of the inflammasome pathway.” Pipeline Updates NLRP3 Portfolio VTX3232 ...

ZyVersa is a clinical-stage biopharmaceutical company with a laser focus on developing first-in-class drugs for diseases that currently have no effective treatments. Its portfolio includes two main ...

Announcing a new publication for Acta Materia Medica journal. Herba Siegesbeckiae (HS) has been traditionally used for ...

ZyVersa Therapeutics (ZVSA) highlights data from an article published in the peer-reviewed International Journal of Nanomedicine titled Small Intestinal Endocrine Cell Derived Exosomal ACE2 Protects ...

Halia Therapeutics, Inc. (Halia), a clinical-stage biopharmaceutical company pioneering innovative treatments for chronic inflammatory diseases, announced today that it will present promising data on ...

Merriman’s research interests also include outcomes in gout, especially severity and drug response. He also applies genetic epidemiological techniques to understanding the causal relationships in gout ...